Community-acquired pneumonia causes great mortality and morbidity and high costs
worldwide. Empirical selection of antibiotic treatment is the cornerstone of management of …

About 200 million cases of viral community-acquired pneumonia occur every year—100
million in children and 100 million in adults. Molecular diagnostic tests have greatly …

Improving the care of adult patients with community-acquired pneumonia (CAP) has been
the focus of many different organizations, and several have developed guidelines for …

Background Pneumococcal pneumonia causes significant morbidity and mortality among
adults. Given limitations of diagnostic tests for non-bacteremic pneumococcal pneumonia …

Background A mismatch between a widespread use of broad-spectrum antibiotic agents and
a low prevalence of reported bacterial co-infections in patients with SARS-CoV-2 infections …

Background The microbial etiology of community-acquired pneumonia (CAP) is still not well
characterized. During the past few years, polymerase chain reaction (PCR)-based methods …

Objective To systematically review longitudinal studies evaluating use of angiotensin
converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and risk of …

Background: In adults, viral causes of community-acquired pneumonia (CAP) are poorly
characterised. The aims of this study were to characterise the viral aetiology of CAP in adults …

Bacterial pneumonia is a major cause of morbidity and mortality in elderly. We hypothesize
that dysbiosis between regular residents of the upper respiratory tract (URT) microbiome …

Background People with chronic obstructive pulmonary disease (COPD) are at increased
risk of pneumococcal disease, especially pneumonia, as well as acute exacerbations with …